BFC Planning’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TVTX
BFC Planning's TVTX Position: Q3 2026 in Review
BFC Planning increased its Travere Therapeutics (TVTX) stake by 18% in Q3 2026, buying an estimated $733 and bringing the position to 79 shares worth $4.65K. The position accounts for ﹤0.01% of the portfolio, ranked #2718.
BFC Planning first reported a position in TVTX in Q4 2025 and has held it in 4 quarters since. 254 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.
- BFC Planning held 79 shares of Travere Therapeutics worth $4.65K as of Q3 2026.
- BFC Planning bought 12 Travere Therapeutics shares in Q3 2026, an estimated $733.
- Travere Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2718 holding.
- BFC Planning first reported a position in Travere Therapeutics in Q4 2025 and has held it in 4 quarters since.
- 254 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.